Catheter Precision, Inc. Reports Results of Operations for Second Quarter 2025
FORT MILL, S.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announced its results of operations for the three and six months ended June 30, 2025.
Highlights of the second quarter include:
Revenue from product sales increased 128% over Q2 2024.
First half 2025 revenue increased 103% over first half 2024.
Sequential quarter over quarter sales increased 48%
The CE Mark for the LockeT product was received during the quarter, with sales expected to start in Europe during the third quarter of this year.
Significant clinical data was presented at the annual Heart Rhythm Society symposium, which included the following:
Accuracy and Long-Term Outcomes from First Multi-Center Registry Experience for Non-Invasive Localization
This data was produced from a multi-center study that enrolled 125 patients. The data demonstrates that VIVO was over 94% accurate, assisted physicians in determining workflow when used pre-procedure, and that the use of VIVO pre-procedure may improve long-term outcomes. Long-term procedural success was over 83%.
Novel Three-Dimensional Mapping Integrating Electrocardiogram Morphology for Difficult-to-Map Premature Ventricular Contractions
This study compiled data from two centers (Heart Hospital of New Mexico and Overland Park Regional Medical Center) and demonstrates how VIVO can improve mapping and ablation for PVCs that are otherwise difficult to map, identify and ablate.
Efficacy and Safety of LockeT in Large-Bore Access Electrophysiological Procedures
The study included 139 patients and demonstrated that LockeT is safe and effective for creating hemostasis in ablation procedures that utilize a large access site like those created by procedures for left atrial appendage occlusion devices and leadless pacemakers.
Diagnostic accuracy of a non-invasive mapping system for scar dependent VT exit site localization: relationship to myocardial scar and successful ablation lesions
This study is novel, and is the first study to demonstrate VIVO's accuracy in scar dependent VT.
VIVO predicted the exit site locations (89%) and had correlation (86%) with the successful ablation sites. At one year follow-up 86% of patients were free from any device therapy.
The acquisition of Cardionomic's heart failure assets was completed by our newly formed 82%-owned subsidiary Cardionomix.
Completed the formation of Kardionav, Inc., a majority-owned joint venture to collaborate on the development of an implant-based software product for the precise location of the ablation site for treating ventricular tachyarrhythmia, a fast heartbeat in the ventricles, a potential product that can serve as the gateway to curing this deadly disease which is not well treated today.
Financial Highlights
Total assets on June 30, 2025, were $25.6 million.
Total shareholders' equity on June 30, 2025, was $6.5 million.
Revenues for the quarter ended June 30, 2025 increased 128% to approximately $212 thousand compared with $93 thousand in the quarter ended June 30, 2024.
Revenues for the six months ended June 30, 2025 increased 103% to approximately $355 thousand compared with $175 thousand in the six months ended June 30, 2024.
Net loss ...
